Analyst Ryan MacDonald of Needham reiterated a Buy rating on Tempus AI, Inc. Class A, retaining the price target of $75.00.
Meet Samuel – Your Personal Investing Prophet
Explore TEMT for 2X leverage on TEMRyan MacDonald has given his Buy rating due to a combination of factors, including Tempus AI’s underappreciated growth prospects despite nearly two years as a public company. He highlights that the firm has built a comprehensive oncology testing platform spanning hereditary risk, treatment selection, and minimal residual disease, positioning it as a key partner for oncologists.
MacDonald also underscores the upside from reimbursement, noting that Tempus AI is still early in this process, which leaves room for average selling prices to rise meaningfully over the next few years. In addition, he points to the company’s differentiated data business, evidenced by strong pipeline activity, large $100M-plus customers, a recently inked Merck agreement, and an upcoming foundation model that together support its status as an emerging AI leader and justify the $75 price target.
According to TipRanks, MacDonald is an analyst with an average return of -10.5% and a 36.00% success rate. MacDonald covers the Technology sector, focusing on stocks such as Docebo, Nerdy, and Duolingo.
In another report released on March 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $95.00 price target.